WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering ex ...

Dyne Therapeutics (DYN) reported new clinical efficacy data from two separate mid to late-stage studies evaluating its two clinical-stage pipeline candidates, DYNE-101 and DYNE-251, in patients with myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping, respectively. New clinical data from both studies demonstrated a meaningful impact on key biomarkers and functional improvement in multiple clinical endpoints that matter to patients. We remind the investo ...

About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life- transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystr ...

Contacts: Investors About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life- transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duc ...

Top-notch biotech stock Dyne Therapeutics (DYN) broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy treatments. Dyne stock catapulted 22.4% to 33.89. Shares hit a record high, topping a buy point at 30.27 out of a consolidation, according to MarketSurge. The biotech stock's relative strength line also launched to a new high. X Top 2% Biotech Stock Dyne studied drugs it calls DYNE-101 and DYNE-251 in patients with myotonic dystrophy type 1 and Duchenne muscular ...

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon ...

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon ...

Core Viewpoint - Dyne Therapeutics is set to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, indicating an update to its previous guidance for the second half of 2024 [1] Group 1: Clinical Trials Overview - The ACHIEVE trial evaluates DYNE-101 in adult patients with myotonic dystrophy type 1 (DM1), designed as a registrational trial with a 24-week multiple ascending dose (MAD) period, a 24-week open-label extension (OLE), and a 96-week long-term extension (LTE) [6] - Enrollment for the ACHIEVE trial is complete with 56 patients and approximately 500 doses administered, focusing on various dosing cohorts [6] - The DELIVER trial assesses DYNE-251 in males with Duchenne muscular dystrophy (DMD), also structured as a registrational trial with similar phases as ACHIEVE, and has enrolled 48 patients with approximately 480 doses administered [6] Group 2: Upcoming Data Release - Dyne plans to report safety and tolerability data from all enrolled cohorts in both trials, along with pharmacokinetic and pharmacodynamic data [6] - Efficacy data will be shared from specific dosing cohorts in the ACHIEVE trial, including results from the 1.8 mg/kg Q4W cohort (n=16) at 12 months, 3.4 mg/kg Q4W cohort (n=16) at 6 months, and 5.4 mg/kg Q8W cohort (n=8) at 3 months [6] - For the DELIVER trial, data on dystrophin expression will be reported from the 10 mg/kg Q4W cohort (n=8) at 6 months [6] Group 3: Company Background - Dyne Therapeutics focuses on developing innovative therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform [5] - The company has a broad pipeline targeting serious muscle diseases, including clinical programs for DM1 and DMD, as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD) [5]

Core Viewpoint - Dyne Therapeutics is set to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, indicating an update to its previous guidance for the second half of 2024 [1] Group 1: Clinical Trials Overview - The ACHIEVE trial evaluates DYNE-101 in adult patients with myotonic dystrophy type 1 (DM1), designed as a registrational trial with a total of 56 patients enrolled and approximately 500 doses administered to date [6] - The DELIVER trial assesses DYNE-251 in males with Duchenne muscular dystrophy (DMD), also designed as a registrational trial with 48 patients enrolled and approximately 480 doses administered to date [6] Group 2: Upcoming Data Release - Dyne plans to report safety and tolerability data from all enrolled cohorts in both trials, along with pharmacokinetic and pharmacodynamic data [6] - Efficacy data will be shared from various dosing cohorts in the ACHIEVE trial, including results from the 1.8 mg/kg cohort at 12 months, the 3.4 mg/kg cohort at 6 months, and the 5.4 mg/kg cohort at 3 months [6] - For the DELIVER trial, data on dystrophin expression will be reported from the 10 mg/kg cohort at 6 months [6] Group 3: Company Background - Dyne Therapeutics focuses on developing innovative therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform [5] - The company has a broad pipeline targeting serious muscle diseases, including clinical programs for DM1 and DMD, as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD) [5]

- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights. "I am excited about the opportun ...